Deciphering Phosphotyrosine-Dependent Signaling Networks in Cancer by SH2 Profiling

Genes and Cancer

Volumn 3, Issue 5-6, 2012, Pages 353-361

  Machida, Kazuya ^a   Khenkhar, Malik ^b   Nollau, Peter ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

cancer; phosphoproteomics; SH2 domain; SH2 profiling; tyrosine phosphorylation

Indexed keywords

IMATINIB; PHOSPHOTYROSINE; PROTEIN SH2; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TYROSINE;

AMINO TERMINAL SEQUENCE; ANALYTIC METHOD; APOPTOSIS; ARTICLE; ASSAY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER RESEARCH; CHRONIC MYELOID LEUKEMIA; FAR WESTERN ANALYSIS; HIGH THROUGHPUT SEQUENCING; HUMAN; NONHUMAN; OLIGONUCLEOTIDE TAGGED MULTIPLEX ASSAY; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PROTEOMICS; QUANTITATIVE ANALYSIS; ROSETTE ASSAY; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 84875495532     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912459048     Document Type: Article

References (50)

1. Bentley DR.Whole-genome re-sequencing.Curr Opin Genet Dev. 2006;16:545-52.
2. Roychowdhury S,Iyer MK,Robinson DR, et al.Personalized oncology through integrative high-throughput sequencing: a pilot study.Sci Transl Med. 2011;3:111ra121.
3. Stratton MR,Campbell PJ,Futreal PA.The cancer genome.Nature. 2008;458:719-24.
4. Burbelo PD,Ching KH,Bren KE,Iadarola MJ.Emerging tactical strategies for fighting the war on cancer based on the genetic landscape.Am J Transl Res. 2011;3:251-8.
5. Harsha HC,Pandey A.Phosphoproteomics in cancer.Mol Oncol. 2010;4:482-95.
6. Kolch W,Pitt A.Functional proteomics to dissect tyrosine kinase signalling pathways in cancer.Nat Rev Cancer. 2010;10:618-29.
7. Hanahan D,Weinberg RA.Hallmarks of cancer: the next generation.Cell. 2011;144:646-74.
8. Nik-Zainal S,Alexandrov LB,Wedge DC, et al.Mutational processes molding the genomes of 21 breast cancers.Cell. 2012;149:979-93.
9. Lobell RB,Omer CA,Abrams MT, et al.Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.Cancer Res. 2001;61:8758-68.
10. Kantarjian H,Sawyers C,Hochhaus A, et al.Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.N Engl J Med. 2002;346:645-52.
11. Giamas G,Man YL,Hirner H, et al.Kinases as targets in the treatment of solid tumors.Cell Signal. 2010;22:984-1002.
12. Pawson T.Regulation and targets of receptor tyrosine kinases.Eur J Cancer. 2002;38:S3-10.
13. Lemmon MA,Schlessinger J.Cell signaling by receptor tyrosine kinases.Cell. 2010;141:1117-34.
14. Krause DS,Van Etten RA.Tyrosine kinases as targets for cancer therapy.N Engl J Med. 2005;353:172-87.
15. Hunter T.Tyrosine phosphorylation: thirty years and counting.Curr Opin Cell Biol. 2009;21:140-6.
16. Gschwind A,Fischer OM,Ullrich A.The discovery of receptor tyrosine kinases: targets for cancer therapy.Nat Rev Cancer. 2004;4:361-70.
17. Baselga J.Targeting tyrosine kinases in cancer: the second wave.Science. 2006;312:1175-8.
18. Ou SH.Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence.Crit Rev Oncol Hematol. 2012;83:407-21.
19. Brennan DJ,O'Connor DP,Rexhepaj E,Ponten F,Gallagher WM.Antibody-based proteomics: fast-tracking molecular diagnostics in oncology.Nat Rev Cancer. 2010;10:605-17.
20. Stasyk T,Huber LA.Mapping in vivo signal transduction defects by phosphoproteomics.Trends Mol Med. 2012;18:43-51.
21. Rush J,Moritz A,Lee KA, et al.Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.Nat Biotechnol. 2005;23:94-101.
22. Rikova K,Guo A,Zeng Q, et al.Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.Cell. 2007;131:1190-203.
23. Geiger T,Cox J,Ostasiewicz P,Wisniewski JR,Mann M.Super-SILAC mix for quantitative proteomics of human tumor tissue.Nat Methods. 2010;7:383-5.
24. Sevecka M,Wolf-Yadlin A,MacBeath G.Lysate microarrays enable high-throughput, quantitative investigations of cellular signaling.Mol Cell Proteomics. 2011;10:M110.005363.
25. Nollau P,Mayer BJ.Profiling the global tyrosine phosphorylation state by Src homology 2 domain binding.Proc Natl Acad Sci U S A. 2001;98:13531-6.
26. Machida K,Thompson CM,Dierck K, et al.High-throughput phosphotyrosine profiling using SH2 domains.Mol Cell. 2007;26:899-915.
27. Dierck K,Machida K,Voigt A, et al.Quantitative multiplexed profiling of cellular signaling networks using phosphotyrosine-specific DNA-tagged SH2 domains.Nat Methods. 2006;3:737-44.
28. Machida K,Mayer BJ.The SH2 domain: versatile signaling module and pharmaceutical target.Biochim Biophys Acta. 2005;1747:1-25.
29. Liu BA,Jablonowski K,Raina M,Arce M,Pawson T,Nash PD.The human and mouse complement of SH2 domain proteins: establishing the boundaries of phosphotyrosine signaling.Mol Cell. 2006;22:851-68.
30. Huang H,Li L,Wu C, et al.Defining the specificity space of the human SRC homology 2 domain.Mol Cell Proteomics. 2008;7:768-84.
31. Bae JH,Lew ED,Yuzawa S,Tome F,Lax I,Schlessinger J.The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site.Cell. 2009;138:514-24.
32. Liu BA,Jablonowski K,Shah EE,Engelmann BW,Jones RB,Nash PD.SH2 domains recognize contextual peptide sequence information to determine selectivity.Mol Cell Proteomics. 2010;9:2391-404.
33. Lim WA,Pawson T.Phosphotyrosine signaling: evolving a new cellular communication system.Cell. 2010;142:661-7.
34. Jadwin JA,Ogiue-Ikeda M,Machida K.The application of modular protein domains in proteomics.FEBS Lett. 2012;586:2586-96.
35. Liu BA,Engelmann B,Nash PD.High-throughput analysis of peptide-binding modules.Proteomics. 2012;10:1527-46.
36. Jones RB,Gordus A,Krall JA,MacBeath G.A quantitative protein interaction network for the ErbB receptors using protein microarrays.Nature. 2006;439:168-74.
37. Machida K,Mayer BJ,Nollau P.Profiling the global tyrosine phosphorylation state.Mol Cell Proteomics. 2003;2:215-33.
38. Dierck K,Machida K,Mayer BJ,Nollau P.Profiling the tyrosine phosphorylation state using SH2 domains.Methods Mol Biol. 2009;527:131-55.
39. Machida K,Mayer BJ.Detection of protein-protein interactions by far-Western blotting.Methods Mol Biol. 2009;536:313-29.
40. Machida K,Eschrich S,Li J, et al.Characterizing tyrosine phosphorylation signaling in lung cancer using SH2 profiling.PLoS One. 2010;5:e13470.
41. Sweeney MC,Wavreille AS,Park J,Butchar JP,Tridandapani S,Pei D.Decoding protein-protein interactions through combinatorial chemistry: sequence specificity of SHP-1, SHP-2, and SHIP SH2 domains.Biochemistry. 2005;44:14932-47.
42. Kuo E,Park DK,Tzvetanova ID,Leiton CV,Cho BS,Colognato H.Tyrosine phosphatases Shp1 and Shp2 have unique and opposing roles in oligodendrocyte development.J Neurochem. 2010;113:200-12.
43. Dubielecka PM,Machida K,Xiong X, et al.Abi1/Hssh3bp1 pY213 links Abl kinase signaling to p85 regulatory subunit of PI-3 kinase in regulation of macropinocytosis in LNCaP cells.FEBS Lett. 2010;584 (15): 3279-86.
44. Kelley LC,Ammer AG,Hayes KE, et al.Oncogenic Src requires a wild-type counterpart to regulate invadopodia maturation.J Cell Sci. 2010;123 (Pt 22): 3923-32.
45. Lazer G,Pe'er L,Farago M,Machida K,Mayer BJ,Katzav S.Tyrosine residues at the carboxy-terminus of Vav1 play an important role in regulation of its biological activity.J Biol Chem. 2010;285 (30): 23075-85.
46. Sriram G,Reichman C,Tunceroglu A, et al.Phosphorylation of Crk on tyrosine 251 in the RT loop of the SH3C domain promotes Abl kinase transactivation.Oncogene. 2011;30 (46): 4645-55.
47. Linardou H,Dahabreh IJ,Kanaloupiti D, et al.Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.Lancet Oncol. 2008;9:962-72.
48. Benesova L,Minarik M,Jancarikova D,Belsanova B,Pesek M.Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors.Anticancer Res. 2010;30:1667-71.
49. Cheung YC,Chang JW,Hsieh JJ,Lin G,Tsai YH.Adequacy and complications of computed tomography-guided core needle biopsy on non-small cell lung cancers for epidermal growth factor receptor mutations demonstration: 18-gauge or 20-gauge biopsy needle.Lung Cancer. 2010;67:166-9.
50. Haura EB.From modules to medicine: How modular domains and their associated networks can enable personalized medicine.FEBS letters. 2012;586:2580-5.